Elliott Sigal

Elliott is a renowned scientific and industry leader who recently served on the board of gene therapy pioneer Spark Therapeutics for five years. During that time, the company developed and launched Luxturna®, the first AAV gene therapy in the United States, and was acquired by Roche for $4.3 billion. Elliott is a former Executive Vice President and Director of Bristol-Myers Squibb (BMS) where he also served as Chief Scientific Officer and President of R&D from 2004 to 2013. Under Elliott’s leadership, 14 new medicines were approved at BMS and in 2012, Scrip Intelligence named him the best R&D Chief in the pharmaceutical industry. Elliott serves as a Senior Advisor to the healthcare team of New Enterprise Associates and is a Board member of Adaptimmune, Surface Oncology, and Vir Biotechnology. He co-chairs the Scientific Advisory Board for Amgen and is a member of the Scientific Steering Committee for the Sean Parker Institute for Cancer Immunology. Elliott received his B.S., M.S. and Ph.D. in Industrial Engineering from Purdue University and M.D. from the University of Chicago.